Guggenheim Initiates Coverage On CymaBay Therapeutics with Buy Rating, Announces Price Target of $20
Portfolio Pulse from richadhand@benzinga.com
Guggenheim analyst Seamus Fernandez has initiated coverage on CymaBay Therapeutics (NASDAQ:CBAY) with a Buy rating and a price target of $20.
August 11, 2023 | 2:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CymaBay Therapeutics has been given a Buy rating by Guggenheim, with a price target of $20.
The Buy rating and price target of $20 announced by Guggenheim for CymaBay Therapeutics indicates a positive outlook for the company. This could potentially attract more investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100